Macaluso FS, et al. - The intention of the authors was to investigate the effectiveness of vedolizumab on intestinal and articular symptoms after 10 and 22 weeks of treatment in inflammatory bowel diseases. Following 10 and 22 weeks of treatment, vedolizumab demonstrated good effectiveness. Findings illustrated that a subset of patients reported improvement also on articular symptoms, possibly due to the concomitant control of gut inflammation.